Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Kintara Therapeutics (KTRA)
NASDAQ:KTRA
Kintara Therapeutics (KTRA) Stock Price & Analysis
581 Followers
KTRA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.80 - $42.08
Previous Close$3.68
Volume4.17K
Average Volume (3M)34.61K
Market Cap
$6.27M
Enterprise Value$12.07M
Total Cash (Recent Filing)$4.87M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-0.2
Beta1.69
Next Earnings
May 18, 2023EPS Estimate
-$0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.10
Shares Outstanding1,675,305
10 Day Avg. Volume47,223
30 Day Avg. Volume34,608
Standard Deviation0.29
R-Squared0.04
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)-1.48
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-0.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Kintara Therapeutics News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KTRA FAQ
What was Kintara Therapeutics’s price range in the past 12 months?
Kintara Therapeutics lowest stock price was $2.80 and its highest was $42.08 in the past 12 months.
What is Kintara Therapeutics’s market cap?
Currently, no data Available
When is Kintara Therapeutics’s upcoming earnings report date?
Kintara Therapeutics’s upcoming earnings report date is May 18, 2023 which is in 51 days.
How were Kintara Therapeutics’s earnings last quarter?
Kintara Therapeutics released its earnings results on Feb 14, 2023. The company reported -$2.1 earnings per share for the quarter, beating the consensus estimate of -$3.15 by $1.05.
Is Kintara Therapeutics overvalued?
According to Wall Street analysts Kintara Therapeutics’s price is currently Overvalued.
Does Kintara Therapeutics pay dividends?
Kintara Therapeutics does not currently pay dividends.
What is Kintara Therapeutics’s EPS estimate?
Kintara Therapeutics’s EPS estimate is -$0.1.
How many shares outstanding does Kintara Therapeutics have?
Kintara Therapeutics has 1,675,305 shares outstanding.
What happened to Kintara Therapeutics’s price movement after its last earnings report?
Kintara Therapeutics reported an EPS of -$2.1 in its last earnings report, beating expectations of -$3.15. Following the earnings report the stock price went down -1.786%.
Which hedge fund is a major shareholder of Kintara Therapeutics?
Currently, no hedge funds are holding shares in KTRA
---
Kintara Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-81.27%
12-Months-Change
Fundamentals
Return on Equity
-182.14%
Trailing 12-Months
Asset Growth
-44.03%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kintara Therapeutics
DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
---
Top 5 ETFs holding KTRA
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold KTRA. The ETFs are listed according to market value of KTRA within the ETF
---
Cyclacel Pharmaceuticals
―
Eterna Therapeutics
―
Bellerophon
―
NeuroBo Pharmaceuticals
―
BioRestorative Therapies
―
---